BIAF
BEARISH
$1.35
Live
bioAffinity Technologies, Inc. · NASDAQ
$1.11
52W Range
$46.53
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$6.07M
P/E
N/A
ROE
-245.2%
Profit margin
-217.5%
Debt/Equity
0.08
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
95%
The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a seemingly healthy Current Ratio of 3.65 and low Debt/Equity of 0.08, the company is deeply unprofitable, with a Profit Margin of -217.50% and ROE of -245.18%. Revenue has collapsed by 38.5% year-over-year, and the stock has lost nearly all value over the past five years, down 99.5%. While the recent 1-month price increase of +9.8% may suggest speculative momentum, fundamentals remain abysmal, and the lack of analyst coverage or target prices underscores minimal market confidence.
Key Strengths
Strong liquidity position with Current Ratio of 3.65 and Quick Ratio of 3.44
Low leverage with Debt/Equity ratio of only 0.08
Positive gross margin of 27.86%, indicating some pricing power or cost control at production level
Recent short-term price rebound of +9.8% over the last month, suggesting potential speculative interest
Float and shares outstanding appear constrained (though data unavailable), which could support volatility on news
Key Risks
Critically low Piotroski F-Score of 1/9 signals high risk of financial failure
Massive and sustained profitability deficits: Operating Margin of -158.56%, ROA of -71.71%
Revenue declining sharply by 38.5% year-over-year, indicating deteriorating business fundamentals
History of consistently missing earnings estimates: 0 out of last 4 quarters beaten, with average surprise of -72.78%
Extreme price collapse: -99.5% over 5 years, -92.9% over 1 year, suggesting long-term structural decline
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
10
Weak
25
10
8
5
0
AI Verdict
Extremely high-risk investment with no current fundamental support
Key drivers: Piotroski F-Score of 1/9, Negative earnings and revenue momentum, Consistent earnings misses, Collapse in market valuation over time
Confidence
96%
Value
25/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 0.52 may suggest asset-based floor
- Price/Sales of 0.90 below sector average
Watchpoints
- No earnings to support valuation (P/E N/A, Forward P/E -2.25)
- No Graham Number or Intrinsic Value available
Future
10/100
Ref Growth rates
Positives
- Most recent Q/Q EPS growth of +7.1% shows minor improvement
Watchpoints
- Revenue Growth (YoY): -38.50%
- No analyst forecasts or target prices available
- No visibility on future earnings growth
Past
8/100
Ref Historical trends
Positives
No standout positives identified.
Watchpoints
- 5Y price change: -99.5%
- 1Y price change: -92.9%
- History of large earnings misses
Health
5/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current Ratio of 3.65 indicates short-term liquidity
- Debt/Equity of 0.08 suggests low financial leverage
Watchpoints
- Piotroski F-Score of 1/9 indicates severe financial weakness
- ROE of -245.18%, ROA of -71.71%
- No Altman Z-Score available, but financials suggest distress
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- Dividend Strength: 0/100
- Payout Ratio: 0.00%
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.35
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BIAF and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BIAF
bioAffinity Technologies, Inc.
Primary
|
-99.5% | -98.4% | -92.9% | -86.5% | +9.8% | -1.5% |
|
QUCY
Mainz Biomed N.V.
Peer
|
-98.2% | -91.0% | -84.9% | -67.3% | -19.4% | +9.9% |
|
SNYR
Synergy CHC Corp.
Peer
|
-94.2% | -94.2% | -78.9% | -80.5% | -60.5% | -8.7% |
|
CANF
Can-Fite BioPharma Ltd.
Peer
|
-99.4% | -91.8% | -87.6% | -68.4% | -9.9% | -4.3% |
|
XTLB
XTL Biopharmaceuticals Ltd.
Peer
|
-81.5% | -49.8% | -49.8% | -50.6% | -5.8% | -1.2% |
BIA
bioAffinity Technologies, Inc.
Primary
5Y
-99.5%
3Y
-98.4%
1Y
-92.9%
6M
-86.5%
1M
+9.8%
1W
-1.5%
QUC
Mainz Biomed N.V.
Peer
5Y
-98.2%
3Y
-91.0%
1Y
-84.9%
6M
-67.3%
1M
-19.4%
1W
+9.9%
SNY
Synergy CHC Corp.
Peer
5Y
-94.2%
3Y
-94.2%
1Y
-78.9%
6M
-80.5%
1M
-60.5%
1W
-8.7%
CAN
Can-Fite BioPharma Ltd.
Peer
5Y
-99.4%
3Y
-91.8%
1Y
-87.6%
6M
-68.4%
1M
-9.9%
1W
-4.3%
XTL
XTL Biopharmaceuticals Ltd.
Peer
5Y
-81.5%
3Y
-49.8%
1Y
-49.8%
6M
-50.6%
1M
-5.8%
1W
-1.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-2.25
PEG Ratio
N/A
P/B Ratio
0.52
P/S Ratio
0.9
EV/Revenue
-0.14
EV/EBITDA
0.09
Market Cap
$6.07M
Profitability
Profit margins and return metrics
Profit Margin
-217.5%
Operating Margin
-158.56%
Gross Margin
27.86%
ROE
-245.18%
ROA
-71.71%
Growth
Revenue and earnings growth rates
Revenue Growth
-38.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.08
Low debt
Current Ratio
3.65
Strong
Quick Ratio
3.44
Excellent
Cash/Share
$1.71
Quarterly Earnings History
EPS performance vs analyst estimates
2025-11-14
$-4.74
-75.6% surprise
2025-08-14
$-5.1
-70.0% surprise
2025-08-14
$N/A
2025-05-15
$-4.8
Healthcare Sector Comparison
Comparing BIAF against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-245.18%
This Stock
vs
-88.14%
Sector Avg
+178.2%
(Excellent)
Profit Margin
-217.5%
This Stock
vs
-16.28%
Sector Avg
+1236.0%
(Superior)
Debt to Equity
0.08
This Stock
vs
2.66
Sector Avg
-97.1%
(Less Debt)
Revenue Growth
-38.5%
This Stock
vs
124.04%
Sector Avg
-131.0%
(Slower)
Current Ratio
3.65
This Stock
vs
4.47
Sector Avg
-18.4%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BIAF
bioAffinity Technologies, Inc.
|
BEARISH | $6.07M | - | -245.2% | -217.5% | $1.35 | |
|
QUCY
Mainz Biomed N.V.
|
BEARISH | $6.09M | - | -488.3% | -% | $0.49 | Compare |
|
SNYR
Synergy CHC Corp.
|
BEARISH | $5.93M | - | -% | -40.6% | $0.52 | Compare |
|
CANF
Can-Fite BioPharma Ltd.
|
BEARISH | $6.23M | - | -178.2% | -% | $2.91 | Compare |
|
XTLB
XTL Biopharmaceuticals Ltd.
|
BEARISH | $5.78M | - | -577.1% | -% | $2.44 | Compare |
BIAF
bioAffinity...
BEARISH
Mkt Cap
$6M
P/E
-
ROE
-245.2%
Price
$1.35
Past News Coverage
Recent headlines mentioning BIAF from our newsroom.
Newest → oldest
No matching news yet.